Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 4/20 | 0.49 |
| ▸ | KDM1A | O60341 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | SSTR1 | P30872 | 3/20 | 0.40 |
| ▸ | SSTR4 | P31391 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2883975 | 1.00 | HTR2C (0.49) | HTR2CKDM1AMAPTPKMSSTR1 | |
| SCHEMBL2878234 | 1.00 | HTR2C (0.49) | HTR2CKDM1AMAPTPKMSSTR1 | |
| SCHEMBL2032036 | 0.86 | BACE1 (0.42) | HTR2CKDM1AMAPTPKM | |
| SCHEMBL2506398 | 0.86 | BACE1 (0.42) | HTR2CKDM1AMAPTPKM | |
| SCHEMBL2506405 | 0.86 | BACE1 (0.42) | HTR2CKDM1AMAPTPKM | |
| SCHEMBL28763024 | 0.85 | KDM1A (0.46) | HTR2CKDM1AMAPTPKMSSTR1 | |
| SCHEMBL17474532 | 0.83 | MAPT (0.40) | MAPTPKM | |
| SCHEMBL17485215 | 0.82 | MAPT (0.60) | HTR2CKDM1AMAPTPKM | |
| Acetic Acid SCHEMBL27922714 | 0.80 | HTR2C (0.46) | HTR2CKDM1AMAPTPKMSSTR1 | |
| SCHEMBL4000731 | 0.80 | MAPT (0.52) | KDM1AMAPTPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7855294-B2 | Cycloalkanopyridine derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-12-21 | — | — | US | disclosed |
| US-20070191419-A1 | Cycloalkanopyridine derivative | MSD K.K. (JP) | 2007-08-16 | — | — | US | disclosed |
| EP-1726590-A1 | CYCLOALKANOPYRIDINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-11-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191419-A1 | Cycloalkanopyridine derivative | OPRL1, OPRK1, AVPR2 | HTR2C 699/4885KDM1A 3484/4885MAPT 287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.